

References

L-28

1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. *JAMA Oncol.* 2019;5(2):173-180.
2. Silvestri GA, Tanner NT, Kearney P, et al; PANOPTIC Trial Team. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. *Chest.* 2018;154(3):491-500.
3. Chu GCW, Lazare K, Sullivan F. Serum and blood based biomarkers for lung cancer screening: A systematic review. *BMC Cancer.* 2018;18(1):181.
4. Barr CE, Funston G, Mounce LTA, Pemberton PW, et al. Comparison of two immunoassays for the measurement of serum HE4 for ovarian cancer. *Pract Lab Med.* 2021;26:e00235.
5. Concors SJ, Sinnamon AJ, Ecker BL, Metz DC, et al. The impact of surgery for metastatic pancreatic neuroendocrine tumor: A contemporary evaluation matching for chromogranin a level. *HPB (Oxford).* 2020;22(1):83-90.
6. Campos-da-Paz M, Dórea JG, Galdino AS, Lacava ZGM, et al. Carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal cancer: Update on biomarker for clinical and biotechnological approaches. *Recent Pat Biotechnol.* 2018;12(4):269-279.
7. Konishi T, Shimada Y, Hsu M, Tufts L, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. *JAMA Oncol.* 2018;4(3):309-315.
8. Hao WJ, Zhang H, Yu Y, Zhao J, et al. [Clinical significance and cost-benefit analysis of serum calcitonin assay in diagnosis and treatment of medullary thyroid carcinoma]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.* 2019;54(7):506-509.
9. Nash Z, Menon U. Ovarian cancer screening: Current status and future directions. *Best Pract Res Clin Obstet Gynaecol.* 2020;65:32-45.
10. Lin DC, Genzen JR. Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. *Breast Cancer Res Treat.* 2018;167(1):269-276.
11. Aparicio J, Sánchez-Muñoz A, Ochendusko S, Gumà J, et al. Treatment and outcome of patients with stage is IS testicular cancer: A retrospective study from the Spanish germ cell cancer group. *J Urol.* 2019;202(4):742-747.
12. Fedorkova L, Ondrus D. Post-treatment persistent alpha-fetoprotein elevation in a patient with testicular cancer. *Klin Onkol.* 2021;34(1):56-58.
13. Hayes, Inc. *Hayes Molecular Test Assessment. Nodify CDT (Biodesix Inc.).* Lansdale, PA: Hayes, Inc.; 04/20/2021.

14. Hayes, Inc. *Hayes Molecular Test Assessment. Nodify XL2 (Biodesix Inc.)*. Lansdale, PA: Hayes, Inc.; 05/13/2021.
15. D'Elia C, Folchini DM, Mian C, et al. Diagnostic value of Xpert (R) Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update. *Ther Adv Urol*. 2021; 13: 1756287221997183.
16. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. *Cancer Biol Med*. 2017;14(1):9-32.
17. Hayes, Inc. *Overa (ASPiRA Labs)*. Lansdale, PA: Hayes, Inc.; 02/01/2018.
18. Hayes, Inc. *Lutetium Lc177 Dotatate (Lutathera, Advanced Accelerator Applications USA Inc) for the treatment of gastroenteropancreatic neuroendocrine tumors*. Lansdale, PA: Hayes, Inc.; 09/05/2019.
19. Dewan R, Dewan A, Jindal M, et al. Diagnostic performance of serum human epididymis protein 4 (HE4) for prediction of malignancy in ovarian masses. *Asian Pac J Cancer Prev*. 2019;20(4):1103-1108.
20. Herold Z, Dank M, Herold M, et al. Histopathological Chromogranin A-positivity is associated with right-sided colorectal cancers and worse prognosis. *Cancers (Basel)*. 2020;13(1):67. Published 2020 Dec 29.
21. Fanget F, Demarchi MS, Maillard, et al. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. *Br J Surg*. 2021;108(9):1064-1071.
22. Ostrin EJ, Sidransky D, Spira A, et al. Biomarkers for lung cancer screening and detection. *Cancer Epidemiol Biomarkers Prev*. 2020;29(12):2411-2415.